Full-Time

Tech Lead Manager

Machine Learning Research

Confirmed live in the last 24 hours

Genesis Therapeutics

Genesis Therapeutics

51-200 employees

AI-driven drug discovery for pharmaceuticals

No salary listed

Senior

Burlingame, CA, USA

This is a hybrid position, requiring some in-office days.

Category
Applied Machine Learning
AI Research
AI & Machine Learning
Software Engineering
Required Skills
Tensorflow
Pytorch
Machine Learning
Requirements
  • PhD in Computer Science, Machine Learning, Physics, or a related field.
  • 4+ years of professional experience in machine learning research, with at least 1+ years in a tech or people leadership role.
  • Strong track record of developing and applying ML methods in areas such as deep learning, generative models, graph neural networks, or equivariant neural networks.
  • Proven expertise in leveraging ML techniques for real-world problems.
  • Experience with state-of-the-art ML frameworks (e.g., PyTorch, TensorFlow, JAX) and distributed computing environments.
  • Demonstrated ability to lead, mentor, and inspire a diverse team of researchers and engineers.
  • Exceptional communication and collaboration skills, with experience bridging the gap between research and application.
  • Strategic thinking with a balance of creativity and execution focus.
Responsibilities
  • Develop and implement the strategic vision for an ML Research team, ensuring alignment with company goals.
  • Serve as a thought leader in state-of-the art ML research, using the latest approaches in diffusion models, equivariant neural nets and predictive ML.
  • Represent Genesis Therapeutics at conferences, workshops, and scientific forums.
  • Guide the team in designing, implementing, and validating novel machine learning models tailored to drug discovery challenges, including molecular property prediction, generative modeling, and protein-ligand interactions.
  • Prioritize and balance short-term project deliverables with long-term foundational research initiatives.
  • Ensure high standards of scientific rigor and reproducibility in research outputs.
  • Partner with cross-disciplinary teams, including computational chemists, software engineers, and drug discovery scientists, to deliver impactful ML-driven solutions.
  • Collaborate with the Engineering team to deploy ML models into scalable production environments.
  • Communicate findings and progress effectively to stakeholders at all levels: from interns to board of directors.
  • Manage budgets, resource allocation, and project timelines for the ML Research group.
  • Identify and establish external collaborations and partnerships to augment in-house capabilities.
  • Lead and mentor a high-performing team of ML Research Scientists and ML Research Engineers.
  • Foster a collaborative, innovative, and growth-oriented team culture.
  • Manage recruitment, performance evaluations, and career development for team members.

Genesis Therapeutics focuses on developing new medicines by using artificial intelligence in the drug discovery process. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables them to explore new chemical spaces and discover novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide their AI-driven drug discovery services. Their goal is to accelerate the development of new drugs through strategic partnerships and successful collaborations, while also generating revenue from upfront payments and potential future earnings based on the success of the drugs they help discover.

Company Size

51-200

Company Stage

Series B

Total Funding

$272.5M

Headquarters

Burlingame, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with NVIDIA enhances AI capabilities for drug discovery.
  • Strategic collaborations expand therapeutic pipeline and address unmet medical needs.
  • Recognition as a 'Fierce 15' company boosts industry credibility.

What critics are saying

  • High competition from AI-driven drug discovery companies like Insilico Medicine.
  • Over-reliance on partnerships could lead to financial instability.
  • Rapid AI advancements may render current models obsolete without continuous innovation.

What makes Genesis Therapeutics unique

  • Genesis uses 3D spatial graph modeling for novel drug candidate generation.
  • The GEMS platform leverages physics-inspired AI for drug discovery.
  • Genesis collaborates with major pharma companies like Eli Lilly and Gilead.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive salary

Equity

Medical, dental, & vision insurance

401(k) program

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

6%

2 year growth

5%
Fierce Biotech
Feb 20th, 2025
Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.

Genetic Engineering & Biotechnology News
Dec 18th, 2024
Genesis Therapeutics Secures Nvidia Investment Boost

Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.

Finsmes
Nov 14th, 2024
Genesis Therapeutics Receives Equity Investment From NVIDIA

Genesis Therapeutics receives equity investment from NVIDIA.

BioPharmaTrend
Nov 13th, 2024
Genesis Therapeutics, NVIDIA Partner; $200M Boost

Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.

ProHost Biotech
Sep 10th, 2024
Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.